Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERCURY trial
2022-000601-27Phase 2Active
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Jun 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retifanlimab, cisplatin, carboplatin and etoposide in Merkel cell carcinoma (MCC), sponsored by Gruppo Oncologico Nord Ovest. Primary endpoint: Pathological complete response rate. Started Jun 2022; status: active.
02
Drugs
retifanlimabcisplatincarboplatinetoposide
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on 2022-000601-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000601-27.